Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus
- PDF / 704,934 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 85 Downloads / 229 Views
Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus Miguel Angel Plasín‑Rodríguez1 · Patricia Patricio1 · Joan Monteagudo2 · Angeles García‑Criado3 · Ricard Cervera1 · Joan Carles Reverter2 · Gerard Espinosa1 · Dolors Tàssies2 Accepted: 26 September 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Microparticles (MPs) have been associated with inflammatory and thrombotic disease. High levels of MPs have been identified in patients with systemic lupus erythematosus (SLE) and associated with cardiovascular disease. We analyzed the procoagulant activity of MPs and its correlation with arteriosclerosis and arterial thrombosis in SLE patients. Eightyseven patients with SLE were included: 22 (25.3%) with associated antiphospholipid syndrome (APS), 32 (36.8%) without antiphospholipid antibodies (aPL) and 33 (37.9%) with aPL but without APS. Subclinical arteriosclerosis, defined as the presence and number of plaques, was evaluated by ultrasonography of carotid arteries. Thrombotic events were confirmed by objective methods. The procoagulant activity of MPs was determined by a functional assay with annexin V. Subclinical arteriosclerosis was found in 19 (21.8%) patients. Thirteen episodes of arterial thrombosis and eight of venous thrombosis were recorded. The procoagulant activity of MPs was greater in patients with arterial thrombosis (17.28 ± 8.29 nM vs 12.96 ± 7.90 nM, p
Data Loading...
